C-POST protocol update: A Phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post surgery and radiation therapy in patients with high-risk cutaneous squamous cell carcinoma

Main Article Content

Danny Rischin
Daniel Brungs
Fiona Day
Hayden Christie
Vishal Patel
Gerard Adams
James Estes Jackson
Maite De Liz Vassen Schurmann
Dmitry Kirtbaya
Thuzar Shin
Christopher Hart
Elizabeth Stankevich
Siyu Li
Israel Lowy
Hyunsil Han
Priscila Gonçalves
Matthew Fury
Sandro Porceddu




1. Breuninger H et al. J Dtsch Dermatol Ges. 2013;11 Suppl 3:37–45, 39–47.

2. Stratigos AJ et al. Eur J Cancer. 2015;51:1989–2007.

3. Porceddu SV et al. J Clin Oncol. 2018;36:1275–1283.

4. Regeneron Pharmaceuticals, Inc. LIBTAYO® (cemiplimab-rwlc) injection, for intravenous use [US prescribing information]; 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf. AccessedJanuary 28, 2022.

5. Health Canada. LIBTAYO® – Notice of compliance with conditions – qualifying notice; 2019. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/libtayonotice-compliance-conditions-218718.html. Accessed January 28, 2022.

6. Brazilian Health Authority – ANVISA. Libtayo (Cemiplimab): new indication; 2021. Available at: https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/libtayo-cemiplimabe-nova-indicacao. Accessed January 28, 2022.

7. Ministry of Health Israel. The Israeli Drug Registry – LIBTAYO; 2019. Available at: https://israeldrugs.health.gov.il/#!/medDetails/164%2099%2036023%2000. Accessed January 28, 2022.

8. Regeneron Pharmaceuticals, Inc. Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma; 2021. Available at: https://www.prnewswire.com/news-releases/libtayo-cemiplimabapproved-by-the-european-commission-as-the-first-immunotherapyindicated-for-patients-with-advanced-basal-cell-carcinoma-301319988.html. Accessed January 28, 2022.

9. Migden MR et al. N Engl J Med. 2018;379:341–351.

10. Migden MR et al. Lancet Oncol. 2020;21:294–305.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>